Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule

Exclusion Criteria

• •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the first dose of vaccine(s) and ending 30 days after the last dose, with exception of BCG vaccination which can be given after the 1 month post-dose 2 or 3 (2-4-11 or 2-3-4-11 months of age schedule) blood sampling and a minimum of 30 days before the pre-booster dose blood sampling.
• •Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and/or S. pneumoniae.
• •History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b disease, and/or invasive pneumococcal diseases.
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
• •History of any neurologic disorders or seizures.
• •Acute disease at the time of enrolment.
• •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
• •A family history of congenital or hereditary immunodeficiency.
• •Major congenital defects or serious chronic illness.
• •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.